Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Tuberculosis

• Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
• 1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam
• Subclinical TB With Innovative Modified Short-course Regimens
• Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
• Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
• Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
• Pragmatic Optimized Rifampicin Trial
• Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis
• TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts
• Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis
• BTZ-043 Dose Evaluation in Combination and Selection
• Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis
• Applying Shear Wave Elastography for Adjunct Steroid on Tuberculous Lymphadenitis
• Sudapyridine (WX-081) in RR-TB Patients
• Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults
• PanACEA - STEP2C -01
• Short-course Regimens for the Treatment of Pulmonary Tuberculosis
• Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
• A Pan-TB Regimen Targeting Host and Microbe
• The BLAST- 1 Trial - Cephalexin+Amoxicillin-clavulanate for Tuberculosis
• Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis
• Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines
• Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis
• The Safety, Completion Rate and Prevention Effect by Rifamycin-containing Regimens for Latent Tuberculosis Infection in Patients With Kidney Transplantation: a Prospective Intervention Pilot Study
• Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis
• A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis
• Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB
• Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis
• Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa
• Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)
• A Phase 1, Drug-Drug Interaction Study to Evaluate Safety, Tolerability, and Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adults
• Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis
• A Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Ethionamide Alone and in Combination With BVL-GSK098
• Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
• Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy
• Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
• One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
• EBA, Safety and Tolerability of Sanfetrinem Cilexetil
• Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
• Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in Combination With Delamanid or Bedaquiline, Delamanid in Combination With Bedaquiline, or Standard of Care in Male and Female Participants Aged 18 to 65 Years With Pulmonary Tub
• Oral Vitamin D and Toll Like Receptor in Spondylitis Tuberculosis
• BCG Revaccination in Children and Adolescents
• A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
• The Prophylaxis of Tuberculosis According to TSPOT Results After Kidney Transplantation
• Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis
• Pharmacogenetics-guided Isoniazid Dosing in TB-HIV
• Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)
• Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
• Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
• Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin
• Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis
• Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung
• Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease
• Linezolid Dosing Strategies in Drug-Resistant TB
• The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis With Positive IGRA
• Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis
• Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)
• Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults
• Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
• Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects
• Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB
• Effect of Smoking Cessation on Tuberculosis Treatment Outcomes
• Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
• Rifampicin at High Dose for Difficult-to-Treat Tuberculosis
• A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2
• Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB
• Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression
• Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)
• Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS
• Treatment Success and Safety of 4 Weeks of Daily Rifapentine and Isoniazid (1HP) vs. 12 Weeks of Weekly Rifapentine and Isoniazid (3HP) for Prevention of Tuberculosis in HIV-uninfected Individuals (1v3HP for TPT in HIV-uninfected Individuals)
• Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide
• Early Bactericidal Activity Safety Pulmonary Tuberculosis Pyrifazimine (TBI-166)
• Evaluating the EBA of Meropenem With Amoxicillin/Clavulanate and Pyrazinamide or Bedaquiline in Adults With PTB
• Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis
• Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081
• Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus
• Phase I Clinical Protocol of BCG-PPD in Healthy People
• Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis
• A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
• Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis
• Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients
• Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis
• Phenotyping of High Dose Rifampicin
• High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis
• Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
• Efficacy of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected Patients
• Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct
• Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults
• Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
• A Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2556286 in Healthy Adult Participants
• Rifampin and the Contraceptive Implant
• Immunization With BCG Vaccine to Prevent Tuberculosis Infection
• Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
• The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants
• Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
• Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study
• A Study in Two Panels of Healthy Adult Participants to Assess Single-Dose Immediate-Release and Single-Dose Dispersible Formulations of Pretomanid
• Novel Triple-dose Tuberculosis Retreatment Regimen
• Pharmacokinetic Evaluation and Local Tolerability of Dry Powder Amikacin Via the Cyclops™
• Economic Evaluation of New MDR TB Regimens
• Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB
• A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant (DR-TB) Pulmonary TB Volunteers (PaSEM)
• Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis
• Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin
• A Multicentre, Cohort Study of Screening and Preventive Intervention for Latent Tuberculosis Infection in Children
• Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion
• Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis
• Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load
• Risk of SDRs Under 3HP and 1HP Regimen for LTBI
• PRACTECAL-PKPD Sub Study
• Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care
• BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
• Adjunctive Linezolid for the Treatment of Tuberculous Meningitis
• 2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.
• Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy
• PanACEA Sutezolid Dose-finding and Combination Evaluation
• Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
• Azacytidine During Anti-tuberculosis Therapy
• Linezolid, Aspirin and Enhanced Dose Rifampicin in HIV-TBM
• Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia
• Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis(SCRIPT-TB)
• Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
• Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
• A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin
• Doravirine, Rifapentine and Isoniazid Interaction
• StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis
• Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)
• Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More
• Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis
• The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB
• Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB
• Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy
• Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis
• Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals
• Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple Dosing
• A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults
• Tuberculosis Clinical Trials Consortium Study 35
• Adjunctive NAC in Adult Patients With Pulmonary Tuberculosis
• A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis
• A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status
• NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB
• Tuberculosis - Learning the Impact of Nutrition
• A Single Ascending Dose Study of BTZ043
• Clinical Study on Adoptive Treatment of MDR-TB With Allogeneic γδT Cells
• Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients
• Pilot Clinical Trial of PRS TB Regimen I - Phase II
• An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis
• Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study)
• Pharmacokinetic Study of Linezolid for TB Meningitis
• Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis
• Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis
• Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
• Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
• Statin Adjunctive Therapy for TB (StAT- TB)
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation
• Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
• Phase 2a Study of PBTZ169
• Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT)
• RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV/TB Co-infection
• Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz
• Treatment of Latent Tuberculosis in Socially Marginalised Citizens
• The Individualized M(X) Drug-resistant TB Treatment Strategy Study
• A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.
• A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers
• A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371
• Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
• Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB
• Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis
• Safety and Immunogenicity Study of GX-70 in TB Patient
• Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB
• Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis
• Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)
• Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings
• Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix)
• First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects
• Phase 1 Study of PBTZ169
• TASK-002: Bioequivalence of Bedaquiline 400mg Administered in Crushed Form Compared to Tablet Form in Healthy Male and Female Adults Under Fed Conditions (BDQ Crush Study)
• Prevention of Tuberculosis in Prisons
• Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals
• Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin
• TB Host Directed Therapy
• Optimizing Treatment to Improve TBM Outcomes in Children
• The Bioavailability of Rifampicin in (FDCs) Widely Used in South Africa to Treat Drug-susceptible (TB)
• Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in HIV-Infected and HIV-Uninfected Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis
• Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis
• Improving the Management of Drug Resistant Tuberculosis in the UK
• A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK
• Using Biomarkers to Predict TB Treatment Duration
• Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
• Pharmacokinetic and Therapeutic Adaptation of Linezolid in the Treatment of Multi-Resistant Tuberculosis
• Doxycycline in Human Pulmonary Tuberculosis
• Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers
• Evaluating Newly Approved Drugs for Multidrug-resistant TB
• The Correlate of Risk Targeted Intervention Study
• Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Pyrazinamide Plus Allopurinol in Healthy Volunteers
• Taima TB: 3HP Study
• A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis
• Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women
• Treatment Shortening of MDR-TB Using Existing and New Drugs
• Infant TB Infection Prevention Study
• FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis
• A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
• Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers
• Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
• The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis
• Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis
• A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis
• A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683
• Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
• Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia
• Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic
• Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan
• The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis
• Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis
• PK Study of Anti-TB Drugs
• An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
• Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention
• Pretomanid in Adults With Hepatic Impairment
• Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly
• PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB
• TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens
• The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
• Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers
• Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Rifampicin in Healthy Volunteers
• Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers
• Heterologous Effects of BCG in Healthy UK Adults
• NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis
• An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
• Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB
• Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis
• Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB
• Shortening Treatment by Advancing Novel Drugs
• A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis
• Research on New Regimens for Retreatment Pulmonary Tuberculosis
• Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis
• A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
• Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana
• A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)
• A Prospective Patient Registry of Patients Exposed to Bedaquiline
• Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis
• Assessing PA-824 for Tuberculosis (the APT Trial)
• A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis
• Brief Bactericidal Activity of Anti-Tuberculosis Drugs
• Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation
• PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)
• Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan
• A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.
• Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection
• High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study
• Optimization of the TB Treatment Regimen Cascade
• Clinical Trial to Investigate the Pharmacokinetics of Second-Line Anti-Tuberculosis Agents
• HRZE Fasted/Fed in Newly Diagnosed TB
• Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide
• Improving Retreatment Success (IMPRESS)
• A Clinical Challenge Study of BCG in Healthy Volunteers
• Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents
• TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial
• Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3
• A Bioequivalence Study of Two Different Dosages of Isoniazid Tablet Formulations in Human Healthy Volunteers
• Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis
• Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection
• Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis
• A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy
• High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB)
• A Pilot Study for Pharmacokinetic Parameter of Colchicine in Patient Taking Rifampin
• ENhance Initiation and Retention in Isoniazid Preventive Therapy (IPT) Care for HIV Study (ENRICH Study)
• Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone
• Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB
• Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)
• Effects of SQ109 on QTc Interval in Healthy Subjects
• A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)
• Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis
• Pharmacokinetic Parameters of Co-trimoxazole
• Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-009)
• Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects
• Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation
• The Efficacy of Silymarin on the Prevention of Hepatotoxicity From Antituberculosis Drugs
• Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design
• Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes
• Indacaterol EfectIveness In COPD Patients With Tuberculosis History
• Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam
• "Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients".
• Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB
• PK/PD of Ertapenem In Patients With TB
• Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment
• Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin
• Immune Reconstitution in Tuberculosis Disease
• Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)
• Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients
• Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease
• Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers
• EARNEST Rifabutin Pharmacokinetics (PK) Substudy
• Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis
• Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)
• Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
• A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis
• Essentiality of INH in TB Therapy
• Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers
• Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT
• Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)
• Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults
• Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin
• Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients
• Intensive Smoking-cessation Intervention Versus Smoking-cessation Advice in Smear-positive Patients With Pulmonary Tuberculosis
• Phase 2a EBA Trial of AZD5847
• Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)
• Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women
• Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis
• Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome (TB-IRIS) Treatment Trial
• Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs
• The Effect of Intermittent Rifampicin on Raltegravir
• Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis
• Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment
• Trial of High-Dose Rifampin in Patients With TB
• Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
• Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI)
• Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment
• Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB
• REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
• Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
• Phase IC Study of Safety and PK of SQ109 300mg Daily
• Acquired Immunodeficiency Syndrome(AIDS) and Tuberculosis(Tb) Co-infection Treatment Strategies Study of China.
• TMC207 +/- Rifabutin/Rifampin
• Study of AERAS 422 in Healthy Adults
• Pharmacokinetics and Safety of Moxifloxacin
• Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)
• Treatment of Mycobacterium Xenopi Pulmonary Infection
• Efficacy of Antituberculous Therapy in Management of Sarcoidosis
• Homeopathy as an Adjuvant to Chemotherapy Improves Clinical Outcome in Relapsed Pulmonary Tuberculosis
• PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay
• QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.
• Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB
• Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)
• Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)
• A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects
• Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations
• Effect of Weight and/or Obesity on Dapsone Drug Concentrations
• Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers
• Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study
• Latency in Pulmonary Tuberculosis
• Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy
• Safety and Pharmacokinetics (PK) in Multidrug-Resistant (MDR) Refractive Tuberculosis
• Replacement of Vitamin D in Patients With Active Tuberculosis
• Treatment Duration for Abdominal Tuberculosis
• Study of Pre-clearance of Latent Tuberculosis Infection And BCG Revaccination
• Isoniazid (INH) Treatment Based on ELISPOT Assay
• Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients
• Effect of Weight and/or Obesity on Ethambutol Drug Concentrations
• High Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis
• Appropriate Timing of HAART in Co-infected HIV/TB Patients
• Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers
• Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers
• Pharmacokinetic Study for Anti-tuberculosis Drugs
• Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)
• Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis
• Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness
• To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.
• Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications
• Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults
• Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis
• Deworming Against Tuberculosis
• Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndrome Trial (THIRST)
• Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis
• TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer
• Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis
• Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis
• Study of Daily Rifapentine for Pulmonary Tuberculosis
• A Trial of Adjunctive Prednisolone and Mycobacterium w Immunotherapy in Tuberculous Pericarditis
• Safety And Efficacy Of Rifabutin In HIV Patients
• Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients
• Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits
• Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children
• Micronutrient Supplementation in in Paediatric Pulmonary Tuberculosis
• Vitamin D in Active Tuberculosis (TB) Study
• An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin
• Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison
• Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis
• A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects
• TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.
• Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment
• NAT2 in Re-challenge of INH in Patients With Hepatitis
• Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis
• Linezolid to Treat Extensively-Drug Resistant Tuberculosis
• Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis
• TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
• Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB)
• A Placebo-controlled, Phase 2 Trial to Evaluate OPC 67683 in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)
• L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB)
• Effectiveness of Alcohol Interventions Among Tuberculosis (TB) Patients in Tomsk Oblast, Russia
• TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB
• Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in Vietnam
• Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa
• Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients
• Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis
• Rapid Diagnosis of Pulmonary Tuberculosis
• Interferon-Gamma Release Assays in Tuberculosis (TB) - HIV Co-infected Children
• Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2)
• PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis
• Investigation of the Effect of N Acetylcysteine Against Anti-Tuberculosis Drugs Induced Liver Toxicity
• Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Latent Tuberculosis
• Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg
• TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral Doses of TMC207 in Subjects With Sputum-Smear Positive Tuberculosis
• A Study to Determine the Best Dose of Antivirals in Patients With Both TB and HIV
• High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis
• Pulmonary Tuberculosis and Vitamin D
• Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)
• MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis
• Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)
• Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin
• Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy
• Pharmacokinetics of Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Tuberculosis
• Efficacy and Safety of Activase (Ateplase) vs Placebo in Complicated Pleural Effusions (CPE)/Empyemas
• Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons
• Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine
• TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).
• Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis
• Metronidazole for Pulmonary Tuberculosis (South Korea)
• Trial of Adjunctive Vitamin D in Tuberculosis Treatment
• A RCT of Prednisone as Adjunctive Therapy for Hospitalized Patients With Pulmonary TB and HIV Co-infection
• The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin
• Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage
• A Randomized Trial of Three Regimens to Prevent Tuberculosis in HIV-Infected Patients With Anergy
• Evaluation of Three Regimens of Chemoprophylaxis for Tuberculosis in Patients co-Infected by HIV and Mycobacterium Tuberculosis
• Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis
• A Study to Compare Three Existing Starting Points of Anti-Retroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients
• Short-Course Isoniazid and Rifampin Compared With Isoniazid for Latent Tuberculosis Infection
• BCG Vaccination Delivered Intradermally, Orally and by Combined Routes
• Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis
• Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis
• Pimonidazole Hydrochloride to Detect Low Oxygen in Tuberculosis-Infected Lungs
• A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients
• Preventive Therapy for Tuberculosis in HIV Infected Persons
• Corticosteroids in the Treatment of Tuberculous Pleurisy
• Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment
• Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children
• A Randomized Trial of DOTS Versus Enhanced DOTS for Community Control of Tuberculosis
• Use TST and QFT-RD1 Test to Monitor the Tuberculous Infection in Patients, Close Contact People and Health Care Workers
• Local Anesthesia and Tuberculin Skin Test in Infants and Children
• Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia
• Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT)
• Treatment of Latent Tuberculosis Infection With Isoniazid
• A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis
• Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis
• Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs
• TB Nutrition, Immunology and Epidemiology
• Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)
• TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment
• TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection
• Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana
• Effects of Vitamin D Supplementation on Antimycobacterial Immunity
• Effect of Multivitamin Supplements on Clinical and Immunological Response in Childhood Tuberculosis
• TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment
• TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment
• A Trial of Isoniazid for the Reversion of Interferon Gamma ELISPOT in Tuberculosis (TB) Case Contacts
• Tuberculosis Treatment Shortening Trial
• Treatment of Latent TB Infection for Jailed Persons
• Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in Haiti
• Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)
• TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy)
• Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults
• Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-limited Settings
• Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis
• Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV
• Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis
• Vitamin A Therapy for Tuberculosis
• Tuberculosis in HIV Infected Patients in Uganda
• Tuberculosis Prevention for HIV Infected Adults
• Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
• TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis
• TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz
• TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TB
• TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine
• TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance
• TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen
• TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TB
• TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis
• Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen
• Randomized Study of Interventions to Enhance Adherence to Isoniazid Prevention Therapy for Tuberculosis in Injection Drug Users
• Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis
• Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis
• Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections
• Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV
• A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy
• Interferon Gamma for Drug Resistant Tuberculosis
• The Treatment of Tuberculosis in HIV-Infected Patients
• Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection
• Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection
• Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis
• A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDR
• A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
• Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection
• Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection